Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204309 | 0.84 | TSHR (0.43) | CYP11B1CYP11B2SIRT2CYP2C19CYP3A4 | |
| SCHEMBL2202154 | 0.78 | CYP11B1 (0.40) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL17651947 | 0.78 | SIRT2 (0.36) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL1479136 | 0.78 | CYP11B1 (0.36) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL845130 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2SIRT2CYP2D6CYP2C19 | |
| SCHEMBL12510466 | 0.75 | SIRT2 (0.35) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL6963184 | 0.74 | CYP11B1 (0.33) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL6965789 | 0.74 | CYP11B1 (0.33) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL1039275 | 0.74 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL12887208 | 0.73 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393800-B1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN ,INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2393800-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091209-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRA2B | CYP11B1 213/4885CYP11B2 138/4885SIRT2 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.